Human Immunodeficiency Virus (HIV) Market to Reach $15 billion in Sales by 2023

MarketResearchReports.Biz has announced addition of new report "PharmaPoint: Human Immunodeficiency Virus (HIV) - Global Drug Forecast And Market Analysis To 2023" to its database.

Human immunodeficiency virus (HIV) is a retrovirus that infects the cells of the immune system, destroying or impairing their function. As the infection progresses, the immune system becomes increasingly weaker, making the infected person more susceptible to other infections. Since the first anti-HIV drug, GlaxoSmithKlines (GSKs) Retrovir (azidothymidine), was approved in 1987, major improvements have been made in the field of antiretroviral therapy (ART). This rapid progress has been headlined by the emergence of once-daily, single-tablet regimens (STRs) such as Gilead Science's Atripla (efavirenz/emtricitabine/tenofovir disoproxil fumarate [TDF]), which offer patients an unparalleled level of convenience.

View Full Report at http://www.marketresearchreports.biz/analysis/487690

GlobalData projects the global HIV marketplace - which, for the purposes of this report, comprises nine major pharmaceutical markets (US, France, Germany, Italy, Spain, UK, Japan, Brazil, China) - to experience modest growth during the forecast period. This growth will be driven primarily by the highly anticipated arrivals of novel integrase inhibitor- (INI-) and protease inhibitor- (PI-) based STRs, which include ViiV Healthcares Triumeq (dolutegravir/abacavir/lamivudine), Gileads Quad 2 (elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide fumarate [TAF]), and Gileads and Janssens darunavir/cobicistat/emtricitabine/TAF. Nevertheless, looming patent expiries of high-grossing branded drugs in the US, 5EU (France, Germany, Italy, Spain, UK), and Japan, along with compulsory licensing and generic erosion in Brazil and China, are expected to curtail market growth.

Download Sample Copy of this Report at http://www.marketresearchreports.biz/sample/sample/487690

Share: